niacinamide has been researched along with Mesothelioma in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
Excerpt | Relevance | Reference |
---|---|---|
"Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy." | 9.17 | Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013) |
"We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures." | 7.85 | The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017) |
"Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 6.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
"Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy." | 5.17 | Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013) |
"We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures." | 3.85 | The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017) |
"Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 2.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pattarozzi, A | 1 |
Carra, E | 1 |
Favoni, RE | 1 |
Würth, R | 1 |
Marubbi, D | 1 |
Filiberti, RA | 1 |
Mutti, L | 1 |
Florio, T | 1 |
Barbieri, F | 1 |
Daga, A | 1 |
Papa, S | 1 |
Popat, S | 1 |
Shah, R | 1 |
Prevost, AT | 1 |
Lal, R | 1 |
McLennan, B | 1 |
Cane, P | 1 |
Lang-Lazdunski, L | 1 |
Viney, Z | 1 |
Dunn, JT | 1 |
Barrington, S | 1 |
Landau, D | 1 |
Spicer, J | 1 |
Pignochino, Y | 1 |
Dell'Aglio, C | 1 |
Inghilleri, S | 1 |
Zorzetto, M | 1 |
Basiricò, M | 1 |
Capozzi, F | 1 |
Canta, M | 1 |
Piloni, D | 1 |
Cemmi, F | 1 |
Sangiolo, D | 1 |
Gammaitoni, L | 1 |
Soster, M | 1 |
Marchiò, S | 1 |
Pozzi, E | 1 |
Morbini, P | 1 |
Luisetti, M | 1 |
Aglietta, M | 1 |
Grignani, G | 1 |
Stella, GM | 1 |
Katz, SI | 1 |
Zhou, L | 1 |
Chao, G | 1 |
Smith, CD | 1 |
Ferrara, T | 1 |
Wang, W | 1 |
Dicker, DT | 1 |
El-Deiry, WS | 1 |
Dubey, S | 1 |
Jänne, PA | 1 |
Krug, L | 1 |
Pang, H | 1 |
Wang, X | 1 |
Heinze, R | 1 |
Watt, C | 1 |
Crawford, J | 1 |
Kratzke, R | 1 |
Vokes, E | 1 |
Kindler, HL | 1 |
Schouwink, H | 1 |
Ruevekamp, M | 1 |
Oppelaar, H | 1 |
van Veen, R | 1 |
Baas, P | 1 |
Stewart, FA | 1 |
2 trials available for niacinamide and Mesothelioma
Article | Year |
---|---|
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; | 2013 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; | 2010 |
4 other studies available for niacinamide and Mesothelioma
Article | Year |
---|---|
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; C | 2017 |
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyt | 2015 |
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracell | 2009 |
Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.
Topics: Animals; Carbon Dioxide; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationsh | 2001 |